Tuberculosis

Pipeline Report Shows Good Prospects for People with HIV, HCV, and TB

An updated summary of experimental therapies for HIV, hepatitis C virus (HCV), and tuberculosis, produced by treatment advocates with i-Base and TAG, shows rapid progress in therapies for HCV and steady progress in the area of HIV.

alt

Simpler TB Therapy Prevents Active Disease in HIV+ People

A combination regimen taken once-weekly for 3 months works as well as a single drug taken daily for 6 months at preventing development of full-blown tuberculosis (TB) disease among HIV positive adults infected with tuberculosis bacteria. alt

Shorter Treatment More Effective for Latent TB

Rifapentine plus isoniazid administered once-weekly for 3 months to treat latent tuberculosis worked better than daily isoniazid for 9 months, with fewer premature treatment discontinuations, researchers reported at the recent American Thoracic Society meeting.

Updated CDC HIV and TB Fact Sheet

The Centers for Disease Control and Prevention (CDC) has issued a revised fact sheet on tuberculosis in people with HIV.

TB Fixed-dose Coformulation Works as Well as Separate Drugs

A 4-drug combination containing rifampicin, isoniazid, pyrazinamide, and ethambutol treats pulmonary tuberculosis (TB) as effectively as individual medications.